Adjuvant chemotherapy for stage D1 adenocarcinoma of prostate

Ralph W deVere White, Richard K. Babayan, John Krikorian, Robert J. Krane, Carl A. Olsson

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

In a series of 112 patients undergoing pelvic lymphadenectomy for clinically localized prostate cancer, 37 were found to have pelvic lymph node metastases. After prostatic irradiation, these 37 patients were divided into groups receiving adjunctive chemotherapy versus no additional treatment. The patients were followed for a period ranging from twelve to sixty-five months for evidence of disease progression. Of the 12 patients administered chemotherapy, disease progression was documented in 4 (average time to progression was fifteen months). In contrast, of the 25 patients receiving no additional treatment, 12 exhibited evidence of gross metastatic disease within an average interval of 11.6 months. One death has been recorded in the chemotherapy group at twenty-nine months after diagnosis; 4 deaths have occurred in patients receiving no systemic therapy (average time to death was eighteen months).

Original languageEnglish (US)
Pages (from-to)270-272
Number of pages3
JournalUrology
Volume21
Issue number3
DOIs
StatePublished - 1983
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Adjuvant chemotherapy for stage D1 adenocarcinoma of prostate'. Together they form a unique fingerprint.

  • Cite this

    deVere White, R. W., Babayan, R. K., Krikorian, J., Krane, R. J., & Olsson, C. A. (1983). Adjuvant chemotherapy for stage D1 adenocarcinoma of prostate. Urology, 21(3), 270-272. https://doi.org/10.1016/0090-4295(83)90085-7